Tenax Therapeutics Inc（TENX）财务数据TENXTenax Therapeutics Inc

Evaluating the bottom line, Tenax Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -59.80%, provide a clear picture of how effectively TENX converts its operational activities into shareholder value.

In the context of the broader market, TENX competes directly with industry leaders such as TELO and MNOV. With a market capitalization of $63.24M, it holds a significant position in the sector. When comparing efficiency, TENX's gross margin of N/A stands against TELO's N/A and MNOV's 69.31%. Such benchmarking helps identify whether Tenax Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Tenax Therapeutics has reported substantial net losses, with Q2 2026 showing a net income loss of $17,803,000, and EPS for the same quarter at -0.35. The current ratio remains strong at 15.07, indicating good liquidity, but the overall financial health is concerning due to continuous losses.